News Quantified

BLUE – bluebird bio, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

Cantor Fitzgerald

Cantor Fitzgerald

Form SC 13G/A bluebird bio, Inc. Filed by: VANGUARD GROUP INC

Form SC 13G/A bluebird bio, Inc. Filed by: GOLDMAN SACHS GROUP INC

Form 4 bluebird bio, Inc. For: Nov 06 Filed by: Tita-Reid Najoh

Form 4 bluebird bio, Inc. For: Nov 06 Filed by: Paulson Richard A.

Form 4 bluebird bio, Inc. For: Nov 06 Filed by: Agwunobi John O

Top News Gainers

12/10 bluebird bio Inc (NASDAQ: BLUE) had its "hold" rating re-affirmed by analysts at William Blair. 13.2%

4/8 Form 4 bluebird bio, Inc. For: Apr 06 Filed by: Smith-Farrell Joanne 9.3%

2/1 bluebird bio Inc (NASDAQ: BLUE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.1%

6/6 bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding ßA-T87Q-globin gene) Approval 8.1%

12/13 bluebird bio Inc (NASDAQ: BLUE) was upgraded by analysts at Oppenheimer Holdings Inc. to a "buy" rating. They now have a $135.00 price target on the stock. 7.0%

12/23 Form 4 bluebird bio, Inc. For: Dec 19 Filed by: WENTWORTH KORY JAMES 6.1%

6/13 bluebird bio Inc (NASDAQ: BLUE) had its "buy" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $195.00 price target on the stock. 5.5%

5/16 bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress 4.8%

10/31 Form 8-K bluebird bio, Inc. For: Oct 31 4.6%

6/14 Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC] 4.3%

Top News Decliners

12/7 bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition -12.0%

2/18 Form 8-K bluebird bio, Inc. For: Feb 18 -9.7%

10/23 bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh -8.7%

8/21 Form 4 bluebird bio, Inc. For: Aug 20 Filed by: Walsh Jeffrey T. -7.3%

6/18 Maxim turns bullish on Bluebird [Seeking Alpha] -6.8%

4/27 Form DEF 14A bluebird bio, Inc. For: Jun 18 -6.8%

6/7 Form 4 bluebird bio, Inc. For: Jun 05 Filed by: Gregory Philip D -6.4%

8/1 Q2/2019 6/30/2019 EPS -3.550 ZacksConsensus -3.030 ActVsEst (0.520) - Miss -6.1%

6/14 Form 8-K bluebird bio, Inc. For: Jun 14 -5.8%

1/13 Form 8-K bluebird bio, Inc. For: Jan 13 -5.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day